Arthur J. Argall III

Arthur J. Argall III is a patent litigation attorney at Williams & Connolly LLP, focusing predominantly on pharmaceutical and biotechnology patent disputes. His practice centers on representing innovator pharmaceutical companies, particularly in matters arising under the Biologics Price Competition and Innovation Act (BPCIA).

Mr. Argall exhibits a strong plaintiff-side preference, having appeared exclusively for plaintiffs in all tracked patent litigation cases. He consistently represents patent owners in enforcing their intellectual property rights against generic and biosimilar manufacturers.

His notable experience includes significant involvement in Regeneron Pharmaceuticals Inc.'s patent enforcement campaigns related to its Eylea® product. He served as counsel in Regeneron's actions against Mylan Pharmaceuticals Inc. (and Biocon Biologics Inc.), Celltrion, Inc., Sandoz Inc., and Amgen Inc. In cases such as Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Mr. Argall was involved in proceedings that resulted in a judgment finding infringement of Regeneron's '865 patent and affirming its validity. He also participated in Federal Circuit appeals where preliminary injunctions for Regeneron against biosimilar applicants were upheld.

While Mr. Argall's profile does not indicate direct representation as counsel in Patent Trial and Appeal Board (PTAB) proceedings, he demonstrates familiarity with inter partes reviews (IPRs) through his co-authored publication discussing False Claims Act cases stemming from IPR proceedings. Furthermore, his prior professional experience includes serving as an attorney in the Office of the Solicitor at the United States Patent and Trademark Office (USPTO) in 2019, providing a foundational understanding of agency procedures. Information regarding his specific bar admissions and educational background is not readily available in publicly sourced materials.